This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellerman, J. E. Articles by Lotze, M. T. Search for Related Content PubMed PubMed Citation Articles by Ellerman, J. E. Articles by Lotze, M. T. Related Collections Tumor Biology: Invasion and Metastasis Cellular Pathobiology: Cancer Genes and Genomics Tumor Biology

Masquerader: High Mobility Group Box-1 and Cancer

Authors' Affiliations: ¹ Department of Surgery, Molecular Genetics, and Biochemistry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania and ² Cell Biology Unit, Instituto Nazionale per la Ricerca sul Cancro y Genoa, Italy

Requests for reprints: Michael T. Lotze, University of Pittsburgh, G.27a Hillman Cancer Center, 5117 Centre Avenue Pittsburgh, PA 15213. Phone: 412-623-6790; Fax: 412-692-2520; E-mail: lotzemt{at}upmc.edu.

Since its identification a third of a century ago, the high-mobility group box-1 (HMGB1) protein has been linked to varied diverse cellular processes, including release from necrotic cells and secretion by activated macrophages engulfing apoptotic cells. Initially described as solely chromatin-associated, HMGB1 was additionally discovered in the cytoplasm of several types of cultured mammalian cells 6 years later. In addition to its intracellular role, HMGB1 has been identified extracellularly as a putative leaderless cytokine and differentiation factor. In the years since its discovery, HMGB1 has also been implicated in disease states, including Alzheimer's, sepsis, ischemia-reperfusion, arthritis, and cancer. In cancer, overexpression of HMGB1, particularly in conjunction with its receptor for advanced glycation end products, has been associated with the proliferation and metastasis of many tumor types, including breast, colon, melanoma, and others. This review focuses on current knowledge and speculation on the role of HMGB1 in the development of cancer, metastasis, and potential targets for therapy.

This article has been cited by other articles:

				S. B. Coffelt and A. B. Scandurro Tumors Sound the Alarmin(s) Cancer Res., August 15, 2008; 68(16): 6482 - 6485. [Abstract] [Full Text] [PDF]

				S. S. Lange, D. L. Mitchell, and K. M. Vasquez High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage PNAS, July 29, 2008; 105(30): 10320 - 10325. [Abstract] [Full Text] [PDF]

				G. C. Prendergast Biological research in cancer: Convergent versus divergent problems Cancer Reviews Online Content, June 1, 2007; 2007(3): 5 - 6. [Full Text] [PDF]